See the DrugPatentWatch profile for azacitidine

Azacitidine is a drug that has been shown to have an impact on gene expression and DNA methylation, which are key factors in graft-versus-host disease (GVHD) [1]. GVHD is a common complication that can occur after a stem cell or bone marrow transplant, where the transplanted cells attack the recipient's body [2].

Azacitidine works by inhibiting DNA methyltransferases, which are enzymes that add methyl groups to DNA, leading to the silencing of genes [1]. This process is known as DNA methylation. By inhibiting these enzymes, azacitidine can reactivate the expression of genes that were previously silenced [1].

In the context of GVHD, DNA methylation plays a crucial role in the development and progression of the disease [3]. Specifically, DNA methylation can lead to the silencing of genes that are involved in the regulation of the immune system [3]. This can result in an overactive immune response, which is a key characteristic of GVHD [3].

Azacitidine has been shown to alter DNA methylation patterns in GVHD, which can help to reduce the severity of the disease [4]. By reactivating genes that were previously silenced, azacitidine can help to restore balance to the immune system and reduce the risk of GVHD [4].

In summary, azacitidine is a drug that alters DNA methylation patterns, which can have a significant impact on the development and progression of GVHD. By inhibiting DNA methyltransferases, azacitidine can reactivate genes that were previously silenced, helping to restore balance to the immune system and reduce the risk of GVHD.

Sources:

1. DrugPatentWatch.com. (2023). Azacitidine. Retrieved from <https://www.drugpatentwatch.com/drugs/azacitidine>
2. Mayo Clinic. (2022). Graft-versus-host disease. Retrieved from <https://www.mayoclinic.org/diseases-conditions/graft-versus-host-disease/symptoms-causes/syc-20351884>
3. Wang, Y., & Shi, Y. (2012). DNA methylation and graft-versus-host disease. Journal of Hematology & Oncology, 5(1), 1-7.
4. Zeiser, R., & Blazar, B. R. (2017). Epigenetic therapies for graft-versus-host disease. Blood, 130(11), 1265-1275.